share_log

港股异动丨君实生物涨超5% 特瑞普利单抗上市许可申请获DO受理

Hong Kong stock changes丨Junshi Biotech rose more than 5%, and the application for marketing license of treprilizumab was accepted by DO

Gelonghui Finance ·  Apr 25 11:34
Gelonghui, April 25 | Junshi Biotech (1877.HK) rallied more than 5% and now reports HK$10.22, with a total market value of HK$10 billion. Junshi Biotech's A shares are currently up 4% to 25.79 yuan. According to the news, the company received a notice from the Drug Administration (DO) of the Hong Kong Department of Health that the marketing license application for treprilimab (product code: TAB001/JS001) combined with cisplatin/gemcitabine as first-line treatment for adult patients with metastatic or recurrent locally advanced nasopharyngeal cancer and as a single agent for recurrent, unresectable or metastatic nasopharyngeal cancer that progresses during or after treatment with previous platinum-containing treatment has been accepted.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment